Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.
Janus kinase (JAK) 2V617F
calreticulin
driver mutations
essential thrombocythemia
hematological characteristics
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
revised:
28
04
2022
received:
20
10
2021
accepted:
01
05
2022
pubmed:
28
6
2022
medline:
25
8
2022
entrez:
27
6
2022
Statut:
ppublish
Résumé
The genetic investigation of essential thrombocythemia(ET) has highlighted the presence of driver mutations in ET. Janus kinase JAK2V617F and calreticulin(CALR) mutations are the most frequent driver mutations and have significantly improved the molecular diagnosis of ET. The impact of genetic heterogeneity on clinical features has not been fully elucidated. This is the first study which aimed to determine the frequency of JAK2V617F and CALR exon9 mutations in Tunisian ET patients and to establish the correlation between hematological characteristics and mutational status. This study included Tunisian patients suspected with ET and was conducted between September 2017 and March 2021. Genomic DNA of patients was isolated from peripheral blood samples. JAK2V617F was detected by AS-PCR and CALR mutations were detected by PCR/direct sequencing. Clinical and hematological characteristics were also analyzed. Two hundred and fifty ET patients were enrolled in this study. JAK2V617F mutation was found in 166/250 (66.4%) of patients, whereas CALR mutations were detected in 27/84 (32.1%) patients without JAK2V617F. Compared with JAK2V617F-positive patients, those with CALR mutations showed lower hemoglobin level and lower leucocytes count (p = 0.007 and p = 0.004,respectively). CALR type 2 was the most frequent mutation of CALR detected in 55.55% of CALR mutated. Six of seven patients with thrombotic events harbored JAK2V617F mutation. The prevalence of driver mutations JAK2V617F or CALR mutations was 77.2% in Tunisian ET patients. Moreover, patients with JAK2 V617F mutation had a higher risk of thrombosis. The mutational status is necessary to improve the diagnosis and contribute to the therapeutic decisions.
Sections du résumé
BACKGROUND
BACKGROUND
The genetic investigation of essential thrombocythemia(ET) has highlighted the presence of driver mutations in ET. Janus kinase JAK2V617F and calreticulin(CALR) mutations are the most frequent driver mutations and have significantly improved the molecular diagnosis of ET. The impact of genetic heterogeneity on clinical features has not been fully elucidated. This is the first study which aimed to determine the frequency of JAK2V617F and CALR exon9 mutations in Tunisian ET patients and to establish the correlation between hematological characteristics and mutational status.
METHODS
METHODS
This study included Tunisian patients suspected with ET and was conducted between September 2017 and March 2021. Genomic DNA of patients was isolated from peripheral blood samples. JAK2V617F was detected by AS-PCR and CALR mutations were detected by PCR/direct sequencing. Clinical and hematological characteristics were also analyzed.
RESULTS
RESULTS
Two hundred and fifty ET patients were enrolled in this study. JAK2V617F mutation was found in 166/250 (66.4%) of patients, whereas CALR mutations were detected in 27/84 (32.1%) patients without JAK2V617F. Compared with JAK2V617F-positive patients, those with CALR mutations showed lower hemoglobin level and lower leucocytes count (p = 0.007 and p = 0.004,respectively). CALR type 2 was the most frequent mutation of CALR detected in 55.55% of CALR mutated. Six of seven patients with thrombotic events harbored JAK2V617F mutation.
CONCLUSION
CONCLUSIONS
The prevalence of driver mutations JAK2V617F or CALR mutations was 77.2% in Tunisian ET patients. Moreover, patients with JAK2 V617F mutation had a higher risk of thrombosis. The mutational status is necessary to improve the diagnosis and contribute to the therapeutic decisions.
Identifiants
pubmed: 35754115
doi: 10.1002/jcla.24522
pmc: PMC9396186
doi:
Substances chimiques
Calreticulin
0
JAK2 protein, human
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24522Informations de copyright
© 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
J Clin Oncol. 2012 Aug 20;30(24):2995-3001
pubmed: 22802311
Int J Biochem Cell Biol. 2012 Jun;44(6):842-6
pubmed: 22373697
Am J Hematol. 2014 Aug;89(8):E121-4
pubmed: 24753125
Oncotarget. 2017 Oct 6;8(60):101735-101744
pubmed: 29254200
Leukemia. 2017 Sep;31(9):1845-1854
pubmed: 28529308
J Clin Oncol. 2011 Aug 10;29(23):3179-84
pubmed: 21747083
Haematologica. 2015 Jul;100(7):893-7
pubmed: 25934766
Cancer Cell. 2005 Apr;7(4):387-97
pubmed: 15837627
Blood. 2017 Dec 7;130(23):2475-2483
pubmed: 29212804
Blood. 2014 Mar 6;123(10):1552-5
pubmed: 24371211
J Clin Pathol. 2021 Dec;74(12):808-811
pubmed: 33144355
Hemasphere. 2021 Jan 27;5(2):e521
pubmed: 33880431
Hematol Transfus Cell Ther. 2020 Jul - Sep;42(3):238-244
pubmed: 31676277
J Clin Lab Anal. 2022 Aug;36(8):e24522
pubmed: 35754115
Blood. 2014 Mar 6;123(10):1544-51
pubmed: 24366362
Blood. 2014 Oct 16;124(16):2507-13; quiz 2615
pubmed: 25037629
Am J Hematol. 2019 Jan;94(1):133-143
pubmed: 30281843
Am J Clin Pathol. 2015 May;143(5):635-44
pubmed: 25873496
Br J Haematol. 2015 Jan;168(1):151-3
pubmed: 25103987
Wien Klin Wochenschr. 2021 Jan;133(1-2):52-61
pubmed: 33215234
Ann Hematol. 2014 Dec;93(12):2029-36
pubmed: 25015052
Indian J Hematol Blood Transfus. 2016 Sep;32(3):262-7
pubmed: 27429517
Blood. 2016 Mar 10;127(10):1307-16
pubmed: 26817954
N Engl J Med. 2019 Nov 28;381(22):2135-2144
pubmed: 31774958
Leuk Res. 2015 Jan;39(1):82-7
pubmed: 25499808
Blood. 2014 Jun 12;123(24):3714-9
pubmed: 24786775
Blood Cancer J. 2015 Nov 27;5:e369
pubmed: 26617062
N Engl J Med. 2013 Dec 19;369(25):2391-2405
pubmed: 24325359
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Orphanet J Rare Dis. 2007 Jan 08;2:3
pubmed: 17210076
Exp Hematol. 2018 Dec;68:62-65
pubmed: 30292681
Blood. 2016 Mar 10;127(10):1325-35
pubmed: 26668133
N Engl J Med. 2013 Dec 19;369(25):2379-90
pubmed: 24325356
Int J Mol Sci. 2021 Mar 25;22(7):
pubmed: 33806036
BMC Cancer. 2020 Mar 12;20(1):205
pubmed: 32164591
Pan Afr Med J. 2021 Jul 12;39:194
pubmed: 34603575
Am J Hematol. 2020 Dec;95(12):1599-1613
pubmed: 32974939
Chin Med J (Engl). 2016 Aug 5;129(15):1778-83
pubmed: 27453224
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187